These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 37397803)
1. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence. Wan GJ; Niewoehner J; Hayes K Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803 [TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Philbin M; Niewoehner J; Wan GJ Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550 [TBL] [Abstract][Full Text] [Related]
3. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review. Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646 [TBL] [Abstract][Full Text] [Related]
4. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis. Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122 [TBL] [Abstract][Full Text] [Related]
5. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047 [TBL] [Abstract][Full Text] [Related]
6. A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States. Nelson WW; Philbin MJ; Gallagher JR; Heap K; Carroll S; Wan GJ Rheumatol Ther; 2017 Dec; 4(2):465-474. PubMed ID: 29071588 [TBL] [Abstract][Full Text] [Related]
7. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus. Askanase AD; Furie RA Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860 [TBL] [Abstract][Full Text] [Related]
8. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review. Mirsaeidi M; Baughman RP Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366 [TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection. Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332 [TBL] [Abstract][Full Text] [Related]
11. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis. Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP Drugs Context; 2022; 11():. PubMed ID: 35382109 [TBL] [Abstract][Full Text] [Related]
12. A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms. Duchowny MS; Chopra I; Niewoehner J; Wan GJ; Devine B J Health Econ Outcomes Res; 2021 Jan; 8(1):1-9. PubMed ID: 33521161 [No Abstract] [Full Text] [Related]
13. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Kaplan J; Miller T; Baker M; Due B; Zhao E Front Neurol; 2020; 11():598496. PubMed ID: 33414758 [No Abstract] [Full Text] [Related]
14. A Narrative Review of Acthar Gel for the Treatment of Myositis. Chandra T; Aggarwal R Rheumatol Ther; 2023 Jun; 10(3):523-537. PubMed ID: 36966453 [TBL] [Abstract][Full Text] [Related]
16. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model. Hayes K; Warner E; Bollinger C; Wright D; Fitch RM BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845 [TBL] [Abstract][Full Text] [Related]
17. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568 [TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687 [TBL] [Abstract][Full Text] [Related]
20. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial. Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]